Literature DB >> 3257430

Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects.

A Amadori1, A De Rossi, G P Faulkner-Valle, L Chieco-Bianchi.   

Abstract

In vitro synthesis of IgG directed against HIV components was detected by ELISA and Western blot assay of lymphocyte culture supernatants. Lymphocytes from HIV-infected individuals spontaneously produced antibody against HIV proteins very early in culture, suggesting in vivo activation of HIV-specific antibody-forming cells. The frequency of circulating B cells spontaneously secreting HIV-specific IgG was very high in some cases, but spontaneous HIV-specific antibody synthesis was not accompanied by polyclonal reactivation of B-cell clones of different specificity. The pattern of specificity of the anti-HIV antibody produced in vitro did not reflect the serum pattern consistently. These findings indicate a new approach potentially useful for the study of the immunobiology of HIV infection. The possible implications of the in vitro production of HIV-specific antibody for the diagnosis, prognosis and clinical management of this infection are also discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257430     DOI: 10.1016/0090-1229(88)90053-0

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  22 in total

1.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Cytomegalovirus-specific B cell activation as a potential marker for the diagnosis of cytomegalovirus infection.

Authors:  M Segondy; J P Vendrell; J Reynes; M F Huguet; B Albat; J Ducos; J C Nicolas; A Serre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

5.  In vitro anti-HIV-1 antibody production in subjects in different stages of HIV-1 infection.

Authors:  S Rusconi; A Riva; L Meroni; G Zehender; F Cocchi; L Scapellato; M Galli
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

6.  Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants.

Authors:  H Pollack; M X Zhan; T Ilmet-Moore; K Ajuang-Simbiri; K Krasinski; W Borkowsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Effects of human immunodeficiency virus encephalitis and drug abuse on the B lymphocyte population of the brain.

Authors:  Iain C Anthony; Dorothy H Crawford; Jeanne E Bell
Journal:  J Neurovirol       Date:  2004-06       Impact factor: 2.643

8.  B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5- B cell subsets.

Authors:  S Indraccolo; M Mion; R Zamarchi; A Veronesi; M L Veronese; M Panozzo; C Betterle; A Barelli; A Borri; A Amadori
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

9.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  Analysis of the spontaneous in vitro anti-HIV-1 antibody secretion by peripheral blood mononuclear cells in HIV-1 infection.

Authors:  J P Vendrell; M Segondy; J Ducos; J Reynes; M F Huguet; J C Nicolas; A Serre
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.